Study highlights impact of government vaccine recommendations and direct-to-consumer pharmaceutical advertising

NewsGuard 100/100 Score

A new study co-authored by a University of Massachusetts Amherst economist reveals the value of government vaccine recommendations to drugmakers, as well as potential benefits of advertising pharmaceuticals directly to consumers -; a practice that is banned in every country apart from the United States and New Zealand. The research is the most comprehensive investigation to date of manufacturer marketing and consumer response to adult vaccine recommendations.

After the U.S. Advisory Committee on Immunization Practices (ACIP) recommended in 2014 that people aged 65 and over receive the pneumococcal vaccine Prevnar 13, Medicare and private insurance plans began covering the vaccine for patients. Pfizer, the sole manufacturer of the vaccine, then launched an advertising blitz to encourage older Americans to get vaccinated. Over the ensuing five years, the number of seniors who received the vaccine increased by about 10%, or 2.5 million people, and sales of Prevnar 13 grew by roughly $1 billion annually.

Our results suggest there is real value to vaccine manufacturers in winning a recommendation from ACIP, and that direct-to-consumer advertising of pharmaceuticals is not the unequivocal boogeyman that some people think it is. It can be an effective tool to achieve public health objectives -; as long as the incentives are aligned."

Brandyn Churchill, assistant professor of resource economics at UMass Amherst

In this case, the incentives were perfectly aligned: ACIP's policy goal was to encourage more older adults to get vaccinated against bacterial pneumonia and Pfizer wanted to sell more vaccines.

Pneumococcal vaccines offer protection against streptococcus pneumoniae, a bacterial infection causing over 500,000 cases of pneumonia in the U.S. each year. Pneumonia is the seventh leading cause of death in the country and hospitalizations related to the disease cost an estimated $9 billion annually.

In addition to increased uptake and sales for Prevnar 13, Churchill and co-authors Laura E. Henkhaus, health economist and data scientist with Hill Physicians Medical Group and Emily C. Lawler, assistant professor of public administration and public policy at the University of Georgia, demonstrate that seniors who received the vaccine were also more likely to have recently visited a health care provider and to have received other vaccinations during those visits, creating what Churchill calls "bundling" of vaccine uptake.

However, the study concludes ACIP's recommendation, and the resulting direct-to-consumer advertising, did nothing to reduce infection and mortality rates from pneumococcal disease.

"We didn't find any evidence of a public health improvement, but someone benefited -; in this case it was Pfizer," Churchill says. 

In 2019, ACIP revised its recommendations, reaffirming that Prevnar 13 is indeed safe and effective, but no longer advising that it be administered as part of routine care for older adults, due to increased uptake of the vaccine by children, which has protected the broader population through the benefits of herd immunity.

"The marketing of Prevnar 13 was a success in that it helped achieve a stated policy goal -; even if that goal changed as ACIP followed the science," Churchill adds.

The complete study appears in the Journal of Policy Analysis and Management.

Journal reference:

Churchill, B. F., et al. (2024). Effect of vaccine recommendations on consumer and firm behavior. Journal of Policy Analysis and Management.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Research expands understanding of vaccine-induced immune thrombocytopenia and thrombosis